Chantana Polprasert1, Yasuhide Takeuchi2, Hideki Makishima2, Kitsada Wudhikarn1, Nobuyuki Kakiuchi2, Kenichi Yoshida2, Thamathorn Arsenasen3, Wimonmas Sitthi3, Panisinee Lawasut1, Sunisa Kongkiatkamon1, Udomsak Bunworasate1, Ponlapat Rojnuckarin1, Seishi Ogawa2 (1.Division of Hematology, Department of Medicine, King Chulalongkorn Memorial Hospital, BKK, Kingdom of Thailand, 2.Department of Tumor biology and pathology, Kyoto University, Kyoto, Japan, 3.Department of Pathology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Kingdom of Thailand)
Session information
Oral Session
Oral Session 1-9B Maliginant lymphoma: Basic (2)
Fri. Oct 12, 2018 10:10 AM - 11:10 AM No.9 (Osaka International Convention Center, 10F 1008)
Chair: Masao Seto (Department of Pathology, Kurume University School of Medicine, Japan)
【E】
Tran B. Nguyen1, Mamiko Sakata-Yanagimoyo1,2, Manabu Fujisawa1, Shigeru Chiba1,2 (1.Hematology, Falcuty of Medicine, Unversity of Tsukuba, Tsukuba, Japan, 2.Hematology, University of Tsukuba Hospital, Tsukuba, Japan)
Stella Amanda1, Regina Wong1, Yan Li2, Zhiyuan Gong2, Takashi Ishida3, Shinsuke Iida4, Takaomi Sanda1 (1.Cancer Science Institute of Singapore, National University of Singapore, Singapore, Republic of Singapore, 2.Department of Biological Sciences, National University of Singapore, Singapore, Republic of Singapore, 3.Division of Hematology and Oncology, Iwate Medical University, Morioka, Japan, 4.Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan)
Noriaki Yoshida1,2, Samuel Y. Ng1, Amanda L. Christie1, Manuel Aivado3, Koichi Ohshima2, Raphael Koch1, David M. Weinstock1 (1.Medical Oncology, DFCI, Boston, MA, USA, 2.Pathology, Kurume Univ, Kurume, Japan, 3.Aileron Therapeutics Inc, Cambridge, MA, USA)
Ola Rizq1, Naoya Mimura2,3, Motohiko Oshima1,4, Shuji Momose5, Yaeko Nakajima-Takagi1,4, Kazumasa Aoyama1, Atsunori Saraya1, Tohru Iseki2,3, Emiko Sakaida3, Chiaki Nakaseko3,6, Yutaka Okuno7, Hiroaki Honda8, Jun-Ichi Tamaru5, Atsushi Iwama1,4 (1.Cel. Mol. Med., Chiba Univ., Chiba, Japan, 2.Trans. Med. Cel. Ther., Chiba Univ. Hosp., Chiba, Japan, 3.Hematol., Chiba Univ. Hosp., Chiba, Japan, 4.Stem Cel. Mol. Med., IMS, Tokyo Univ., Tokyo, Japan, 5.Pathol., Saitama Med. Center, Saitama Med. Univ., Saitama, Japan, 6.Hematol., Int. Univ. Health and Welfare, Narita, Japan, 7.Hematol. Rheumatol. Infectious Dis., Kumamoto Univ., Kumamoto, Japan, 8.Human Dis. Models, Tokyo Women's Med. Univ., Tokyo, Japan)
Jakrawadee Julamanee1, Kitsada Wudhikarn2, Udomsak Bunworasate2, Arnuparp Lekhakula1, Archrob Kuhapinan3, Suporn Chancharunee4, Tanin Intragumtornchai2 (1.Faculty of Medicine, Prince Songkhla University, Songkhla, Kingdom of Thailand, 2.Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Kingdom of Thailand, 3.Faculty of Medicine, Siriraj Hospital, Bangkok, Kingdom of Thailand, 4.Faculty of Medicine, Ramathibodi Hospital, Bangkok, Kingdom of Thailand)